| Trial ID: | L1889 |
| Source ID: | NCT02914691
|
| Associated Drug: |
Dapagliflozine 10 Mg Once Daily Tablet Treatment
|
| Title: |
Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
|
| Acronym: |
DapKid
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Diabetic Nephropathy
|
| Interventions: |
DRUG: Dapagliflozine 10 mg once daily tablet treatment|DRUG: Placebo identical once daily tablet treatment
|
| Outcome Measures: |
Primary: Change in Urinary Peptide Patterns (Proteomics), Proteomics will be evaluated at week 0, at crossover week 12 (+/- 1 week), and at end study week 24 (+/- 1 week), Up to 26 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Peter Rossing
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2015-08
|
| Completion Date: |
2017-07-05
|
| Results First Posted: |
|
| Last Update Posted: |
2018-09-10
|
| Locations: |
Steno Diabetes Center, Gentofte, 2820, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02914691
|
